Literature DB >> 17997394

Loss of visual field among patients with birdshot chorioretinopathy.

Jennifer E Thorne1, Douglas A Jabs, Sanjay R Kedhar, George B Peters, James P Dunn.   

Abstract

PURPOSE: To describe the prevalence and incidence of loss of visual field among patients with birdshot chorioretinopathy (BSCR) and to describe the effect of therapy on such field loss in these patients.
DESIGN: Retrospective cohort study.
SETTING: Single-center, academic practice. STUDY POPULATION: Fifty-five patients with BSCR evaluated from January 1984 through July 2006. PROCEDURES: Demographic, clinical, and visual field data were collected retrospectively. OUTCOME MEASURES: Visual field loss is defined as an abnormal visual field score on Goldmann perimetry within six months of presentation and during follow-up; rate of visual field loss is defined as the number of degrees lost per year.
RESULTS: Forty-eight eyes of 24 patients had Goldmann visual fields performed within six months of presentation and of these eyes, 75% and 56% had abnormal field scores for the I-4 and IV-4 isopters, respectively. Of the 28 eyes of 14 patients that received immunosuppressive drug therapy during the follow-up period, the rate of visual field "loss" prior to treatment was 107 degrees/year (95% confidence interval [CI]: 65, 148 degrees/year) and 56 degrees/year (95% CI: 5, 109 degrees/year) for the I-4 and IV-4 isopters, respectively. The rate of "gain" after institution of immunosuppressive drug therapy was 53 degrees/year (95% CI: 10 degrees lost/year, 98 degrees gained/year) and 30 degrees/year (95% CI: 20 degrees lost/year, 81 degrees gained/year) for each isopter.
CONCLUSIONS: Visual field loss was common among our patients with BSCR. Usage of immunosuppressive drug therapy may reverse some of the visual field loss while therapy is employed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997394     DOI: 10.1016/j.ajo.2007.08.039

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  25 in total

1.  Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.

Authors:  Ryan B Rush; Debra A Goldstein; David G Callanan; Beeran Meghpara; William J Feuer; Janet L Davis
Journal:  Am J Ophthalmol       Date:  2011-02-01       Impact factor: 5.258

Review 2.  Immunosuppression for the Uveitides.

Authors:  Douglas A Jabs
Journal:  Ophthalmology       Date:  2017-09-20       Impact factor: 12.079

Review 3.  New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2015-02-14       Impact factor: 2.031

4.  Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.

Authors:  Douglas A Jabs; Alka Ahuja; Mark L Van Natta; Alice T Lyon; Steven Yeh; Ronald Danis
Journal:  Ophthalmology       Date:  2015-04-17       Impact factor: 12.079

5.  Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.

Authors:  Bryn M Burkholder; Jiangxia Wang; James P Dunn; Quan D Nguyen; Jennifer E Thorne
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

6.  Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.

Authors:  Oren Tomkins-Netzer; Susan Lightman; Lea Drye; John Kempen; Gary N Holland; Narsing A Rao; Richard J Stawell; Albert Vitale; Douglas A Jabs
Journal:  Ophthalmology       Date:  2015-09-07       Impact factor: 12.079

7.  Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease.

Authors:  Ozlem Balci; Bruno Jeannin; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2017-03-15       Impact factor: 2.031

8.  Visual field loss in patients with cytomegalovirus retinitis.

Authors:  Jennifer E Thorne; Mark L Van Natta; Douglas A Jabs; Jacque L Duncan; Sunil K Srivastava
Journal:  Ophthalmology       Date:  2010-12-13       Impact factor: 12.079

9.  Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome.

Authors:  Sapna Gangaputra; Lea Drye; Vijay Vaidya; Jennifer E Thorne; Douglas A Jabs; Alice T Lyon
Journal:  Am J Ophthalmol       Date:  2012-10-12       Impact factor: 5.258

10.  Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.

Authors:  David G Birch; Patrick D Williams; David Callanan; Robert Wang; Kirsten G Locke; Donald C Hood
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.